



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 8345**  
Shigeo OHTA et al. : Attorney Docket No. 2005\_1500A  
Serial No. 10/550,280 : Group Art Unit 1643  
Filed September 23, 2005 : Examiner Christopher H. Yaen  
  
CELL DEATH-INDUCING FUSION  
GENE SPECIFICALLY ACTING  
ON CANCER AND PRODUCT THEREOF : **Mail Stop: AMENDMENT**

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In response to the Restriction Requirement dated January 10, 2008, Applicants hereby elect the invention identified as Group 2 (claims 1-8), drawn to a fusion gene comprising a homing signal, a GFP gene, and a delta-NBax gene, in which the homing signal is NGR peptide sequence.

Favorable action on the merits is now requested.

Respectfully submitted,

Shigeo OHTA et al.

By: 

William R. Schmidt, II  
Registration No. 58,327  
Attorney for Applicants

WRS/lq  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
February 5, 2008